ATCvet code: QG04BX91
Pharmacodynamics
The clinical effect of phenylpropanolamine in urinary incontinence is based on its stimulation effect on α-adrenergic receptors. This causes an increase in, and a stabilisation of, the closure pressure in the urethra, which is innervated mainly by adrenergic nerves.
Phenylpropanolamine is a racemic mixture of D and L enantiomers.
Pharmacokinetics
In the dog, the mean half-life of Phenylpropanolamine is approximately 3 hours with maximal plasma concentrations being found after approximately 1 hour. No accumulation of phenylpropanolamine has been observed after a dose of 1 mg/kg 3 times daily over 15 days.
When the veterinary medicinal product is administered to a fasted dog, bioavailability is increased significantly.